Back to News
Market Impact: 0.4
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
Source: businesswire.com
Healthcare & Biotech
Sac-TMT reduced the risk of death by 32% and the risk of disease progression or death by 41% versus chemotherapy in the TroFuse-005 trial, according to the announcement. The headline does not provide additional trial details or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
MRK0.80
More News
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results